Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib vs continuation of biologic therapy in multi-treated metastatic colorectal cancer
2016-002222-37Phase 2Terminated
- Sponsor
- Herlev og Gentofte Hospital
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of regorafenib in metastatic colon cancer (mCRC) (2 arms), sponsored by Herlev og Gentofte Hospital. Primary endpoint: Overall survival. Started Jun 2016; status: terminated.
02
Drugs
regorafenib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2016-002222-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002222-37.